A Case of JAK2V617F-Negative Myeloproliferative Neoplasm in a Young Female Presenting With Extreme Thrombocytosis

被引:0
|
作者
Kumar, Kelash [1 ]
Koubeissy, Assile [1 ]
Pulenthiran, Arichanah [1 ]
Kumar, Amrat [2 ]
Gulati, Amit [1 ]
Wolf, Brian [3 ]
Peeke, Stephen [3 ]
机构
[1] Maimonides Hosp, Dept Internal Med, Brooklyn, NY 11219 USA
[2] Bassett Med Ctr, Dept Internal Med, Cooperstown, NY USA
[3] Maimonides Hosp, Dept Hematol & Oncol, Brooklyn, NY 11219 USA
关键词
hydroxyurea use; splenomegaly; jak inhibitor; extreme thrombocytosis; chronic myeloid leukemia (cml); CHRONIC MYELOID-LEUKEMIA;
D O I
10.7759/cureus.50679
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombocytosis is a commonly observed condition in clinical practice and typically results from various pathophysiological factors, such as iron deficiency, blood loss, infection, medications, rheumatologic conditions, malignancy, asplenia, post-splenectomy, or familial factors. However, extreme thrombocytosis, defined as a platelet count > 10,000 K/UL (equal or greater than a million), is a rare occurrence. In this report, we present a compelling case of severe thrombocytosis attributed to underlying chronic myelogenous leukemia (CML), further complicated by coexisting iron deficiency. It is essential to emphasize that not all instances of extreme thrombocytosis are indicative of essential thrombocythemia. Hence, maintaining a high level of suspicion for non-ET myeloproliferative neoplasms (MPNs) such as CML, as well as other underlying conditions like iron deficiency anemia, is crucial for accurate diagnosis and timely management.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Detection of Myeloproliferative Leukemia W515L/K Mutation in JAK2v617F-Negative Myeloproliferative Neoplasms
    Punia, Jyotinder Nain
    Meng, Xiuling
    Zhuang, Yi
    Sayedian, Farzaneh
    Crisan, Domnita
    Maine, Gabriel
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (04) : 664 - 664
  • [2] Prevalence of JAK2V617F, CALR in Philadelphia Positive and Negative Myeloproliferative Neoplasm
    Abedi, Elham
    Karimi, Mehran
    Cohan, Nader
    Haghpanah, Sezaneh
    Yaghobi, Ramin
    Azarpira, Negar
    Moghadam, Mohamad
    Bayat, Elahe
    Farokhian, Farnoush
    Mohammadi, Hamid
    Lak, Elahe Razmara
    Golafshan, Habib Allah
    Ramzi, Mani
    GALEN MEDICAL JOURNAL, 2021, 10
  • [3] MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms
    Patnaik, M. M.
    Lasho, T. L.
    Finke, C. M.
    Gangat, N.
    Caramazza, D.
    Siragusa, S.
    Hanson, C. A.
    Pardanani, A.
    Tefferi, A.
    LEUKEMIA, 2010, 24 (04) : 859 - 860
  • [4] Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: A case report
    Pemmaraju N.
    Hamilton J.P.
    Cameron A.M.
    Sisson S.
    Moliterno A.R.
    Journal of Medical Case Reports, 6 (1)
  • [5] MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms
    M M Patnaik
    T L Lasho
    C M Finke
    N Gangat
    D Caramazza
    S Siragusa
    C A Hanson
    A Pardanani
    A Tefferi
    Leukemia, 2010, 24 : 859 - 860
  • [6] Plummer-Vinson syndrome and reactive thrombocytosis mask a JAK2-V617F positive myeloproliferative neoplasm
    Scott, Emma Catherine
    Schuster, Stephen
    BLOOD, 2011, 118 (23) : 5988 - 5988
  • [7] JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis
    Salhotra, Amandeep
    Oo, Thein H.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2014, 30 : S4 - S8
  • [8] Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia
    E Puigdecanet
    B Espinet
    J J Lozano
    L Sumoy
    B Bellosillo
    L Arenillas
    A Álvarez-Larrán
    F Solé
    S Serrano
    C Besses
    L Florensa
    Leukemia, 2008, 22 : 1368 - 1376
  • [9] JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis
    Amandeep Salhotra
    Thein H. Oo
    Indian Journal of Hematology and Blood Transfusion, 2014, 30 : 4 - 8
  • [10] JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera
    Rothlisberger, Benno
    Huber, Andreas
    Bargetzi, Mario
    Mendez, Adriana
    Heizmann, Marc
    LEUKEMIA & LYMPHOMA, 2008, 49 (03) : 586 - 588